| Name | Title | Contact Details |
|---|
Rees Broome, PC is a leading law firm located in Virginia, recognized for its extensive legal services and interdisciplinary approach to complex legal matters. The firm has established itself as one of the top law firms in the state, featuring a team of award-winning attorneys with diverse expertise. The firm offers a variety of legal services, including civil litigation, construction law, mergers and acquisitions, and corporate law. Rees Broome is particularly noted for its national ranking in construction litigation and its Tier 1 rankings in business organizations and corporate law. Additionally, the firm provides legal counsel for community associations, addressing issues related to land use, employment, and insurance coverage law. Rees Broome serves a wide range of clients, including community associations, businesses, and individuals involved in various legal challenges.
Based in North Carolina, the partnership of UNX and Christeyns brings together more than 100 years of experience in the textile care industry. Specializing in commercial quality cleaning chemicals for the laundry, housekeeping, warewashing, and dry and wet cleaning markets, these products are supported with custom designed dispensing equipment to produce high efficiency results for customers. Learn more by calling 800-869-6171 for more information or by visiting our website.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.